Earnings call transcript: CSL shares jump 16.4% after FY 2026 reset year
CSL Limited reported FY 2026 as a "reset year" for its Australian biotech and plasma specialist. Despite a 1% decline in revenue to $15.8 billion on a constant-currency basis, investors focused on signs of growth, strong cash flow, and a larger buyback. Underlying NPAT-A fell 2% to $3.1 billion, while statutory net profit turned into a $2.6 billion loss due to $6.0 billion in post-tax restructuring and impairment charges.
The stock surged 16.4% to $156.68, highlighting investors' focus on the company's forward outlook, cost savings, and capital returns. Despite the statutory loss, CSL remained profitable on an underlying basis, with operating cash flow reaching $3.5 billion. CSL is guided to about 5% NPAT growth in FY 2027, with CSL Behring expected to deliver mid-single-digit revenue growth and Vifor facing a 25% revenue decline.
Seqirus is forecast to post low-single-digit revenue growth, driven by new markets and the first season of Algemflu in the U.K.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
